Assessing overdiagnosis of fecal immunological test screening for colorectal cancer with a digital twin approach.


Journal

NPJ digital medicine
ISSN: 2398-6352
Titre abrégé: NPJ Digit Med
Pays: England
ID NLM: 101731738

Informations de publication

Date de publication:
10 Feb 2023
Historique:
received: 27 05 2022
accepted: 21 01 2023
entrez: 10 2 2023
pubmed: 11 2 2023
medline: 11 2 2023
Statut: epublish

Résumé

Evaluating the magnitude of overdiagnosis associated with stool-based service screening for colorectal cancer (CRC) beyond a randomized controlled trial is often intractable and understudied. We aim to estimate the proportion of overdiagnosis in population-based service screening programs for CRC with the fecal immunochemical test (FIT). The natural process of overdiagnosis-embedded disease was first built up to learn transition parameters that quantify the pathway of non-progressive and progressive screen-detected cases calibrated with sensitivity, while also taking competing mortality into account. The Markov algorithms were then developed for estimating these transition parameters based on Taiwan FIT service CRC screening data on 5,417,699 residents aged 50-69 years from 2004 to 2014. Following the digital twin design with the parallel universe structure for emulating the randomized controlled trial, the screened twin, mirroring the control group without screening, was virtually recreated by the application of the above-mentioned trained parameters to predict CRC cases containing overdiagnosis. The ratio of the predicted CRCs derived from the screened twin to the observed CRCs of the control group minus 1 was imputed to measure the extent of overdiagnosis. The extent of overdiagnosis for invasive CRCs resulting from FIT screening is 4.16% (95% CI: 2.61-5.78%). The corresponding figure is increased to 9.90% (95% CI: 8.41-11.42%) for including high grade dysplasia (HGD) and further inflated to 15.83% (95% CI: 15.23-16.46%) when the removal adenoma is considered. The modest proportion of overdiagnosis modelled by the digital twin method, dispensing with the randomized controlled trial design, suggests the harm done to population-based FIT service screening is negligible.

Identifiants

pubmed: 36765093
doi: 10.1038/s41746-023-00763-5
pii: 10.1038/s41746-023-00763-5
pmc: PMC9918445
doi:

Types de publication

Journal Article

Langues

eng

Pagination

24

Subventions

Organisme : Ministry of Science and Technology, Taiwan (Ministry of Science and Technology of Taiwan)
ID : 111-2118-M-002 -004 -MY2
Organisme : Ministry of Science and Technology, Taiwan (Ministry of Science and Technology of Taiwan)
ID : MOST 110-2811-M-002 -633

Informations de copyright

© 2023. The Author(s).

Références

Gastroenterology. 2018 Nov;155(5):1383-1391.e5
pubmed: 30031768
Med Decis Making. 2018 Apr;38(1_suppl):54S-65S
pubmed: 29554469
Gastroenterology. 2011 Jun;140(7):2116-25
pubmed: 21354148
J Cutan Med Surg. 2010 Jan-Feb;14(1):24-9
pubmed: 20128987
Trends Endocrinol Metab. 2019 Jul;30(7):432-444
pubmed: 31151733
N Engl J Med. 1993 May 13;328(19):1365-71
pubmed: 8474513
Gastroenterology. 2018 Sep;155(3):592-595
pubmed: 30076834
Ann Intern Med. 2014 Jul 15;161(2):104-12
pubmed: 25023249
Science. 2021 Mar 12;371(6534):1105-1106
pubmed: 33707255
Biometrics. 2000 Mar;56(1):167-72
pubmed: 10783792
Biom J. 2012 Jan;54(1):20-44
pubmed: 22213054
Lancet. 1996 Nov 30;348(9040):1467-71
pubmed: 8942774
Stat Med. 2020 Feb 28;39(5):660-673
pubmed: 31855293
BMJ Open. 2019 Mar 10;9(3):e022457
pubmed: 30858156
Biostatistics. 2004 Oct;5(4):603-13
pubmed: 15475422
J Natl Cancer Inst. 2009 Mar 18;101(6):374-83
pubmed: 19276453
Biometrics. 2008 Mar;64(1):10-9
pubmed: 17501937
Cancer. 1999 Oct 1;86(7):1116-28
pubmed: 10506694
J Med Screen. 2019 Sep;26(3):135-138
pubmed: 30987504
Science. 2021 Sep 24;373(6562):1474-1479
pubmed: 34554797
Gut. 2015 May;64(5):784-90
pubmed: 25179811
Gut. 2021 Dec;70(12):2321-2329
pubmed: 33495268
J Natl Cancer Inst. 2015 May 06;107(7):
pubmed: 25948872
JAMA. 2018 May 8;319(18):1901-1913
pubmed: 29801017
Br J Cancer. 2006 Aug 7;95(3):401-5
pubmed: 16832417
Cancer. 2016 Jun 1;122(11):1680-8
pubmed: 27061710
Br J Surg. 2008 Aug;95(8):1029-36
pubmed: 18563785
Clin Exp Gastroenterol. 2015 Sep 09;8:279-84
pubmed: 26392783
Lancet. 1996 Nov 30;348(9040):1472-7
pubmed: 8942775
Scand J Prim Health Care. 2019 Jun;37(2):145-154
pubmed: 31079520
Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1219-28
pubmed: 20406961
Science. 2019 Apr 12;364(6436):127-128
pubmed: 30975876
BMJ Open. 2021 Apr 14;11(4):e042158
pubmed: 33853794

Auteurs

Ting-Yu Lin (TY)

Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan.

Sherry Yueh-Hsia Chiu (SY)

Department of Health Care Management, College of Management, Chang Gung University, Taoyuan, Taiwan.
Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.

Ling-Chun Liao (LC)

Department of Pharmacy, National Taiwan University Hsin-Chu Hospital, Hsinchu, Taiwan.

Sam Li-Sheng Chen (SL)

School of Oral Hygiene, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan.

Han-Mo Chiu (HM)

Departments of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. hanmochiu@ntu.edu.tw.

Tony Hsiu-Hsi Chen (TH)

Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan. chenlin@ntu.edu.tw.

Classifications MeSH